Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | PI4KA | P42356 | 3/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.57 |
| ▸ | AHCY | P23526 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17165347 | 0.87 | EGFR (0.66) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL27713663 | 0.86 | EGFR (0.64) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL983769 | 0.84 | ADORA2A (0.68) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL7199253 | 0.84 | ADORA2A (0.62) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL455646 | 0.82 | P2RX7 (0.49) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL17297723 | 0.82 | ADCY5 (0.74) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL6694591 | 0.82 | EGFR (0.60) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| Acetic Acid SCHEMBL4107415 | 0.81 | ADORA2A (0.82) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL6045746 | 0.81 | ADCY5 (0.74) | EGFRALDH1A1ADORA2AADORA1PI4KA | |
| SCHEMBL23885424 | 0.81 | P2RX7 (0.66) | EGFRALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190262794-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC | 2019-08-29 | — | — | US | claimed |
| EP-3402897-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2018-11-21 | — | — | EP | claimed |
| WO-2017117292-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC (US) | 2017-07-06 | — | — | WO | claimed |
| CN-101157703-A | Adenine bisphosphonate and preparation method thereof and application in pharmaceutical preparations | UNIV HEBEI MEDICAL (CN) | 2008-04-09 | — | — | CN | claimed |
| EP-0792283-A1 | SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH | CHIRON CORPORATION (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1996015143-A1 | SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH | CHIRON CORPORATION (US) | 1996-05-23 | — | — | WO | claimed |
| US-20230294064-A1 | SUBSTRATES, SYSTEMS, AND METHODS FOR NUCLEIC ACID ARRAY SYNTHESIS | VIBRANT HOLDINGS, LLC | 2023-09-21 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115427044-A | Pyrrolopyrimidines as complement inhibitors | 拜奥克里斯特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-04-26 | — | — | US | disclosed |
| EP-0639607-B1 | Method and apparatus for degradation and sequencing of polymers which sequentially eliminate terminal residues | PERSEPTIVE BIOSYSTEMS INC (US) | 1998-01-07 | — | — | EP | disclosed |
| EP-0792283-A1 | SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH | CHIRON CORPORATION (US) | 1997-09-03 | — | — | EP | disclosed |
| US-5527675-A | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues | MILLIPORE CORPORATION (US) | 1996-06-18 | — | — | US | disclosed |
| WO-1996015143-A1 | SYNTHESIS OF PEPTIDE NUCLEIC ACIDS (PNAs) AND ANALOGUES VIA SUBMONOMER APPROACH | CHIRON CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
| EP-0639607-A2 | Method and apparatus for degradation and sequencing of polymers which sequentially eliminate terminal residues | PERSEPTIVE BIOSYSTEMS, INC. (US) | 1995-02-22 | — | — | EP | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | EGFR 2721/4885ALDH1A1 1325/4885ADORA2A 1283/4885 |
| US-11311520-B2 | Substituted dihydroimidazopyridinediones as MKNK1 and MKNK2 inhibitors | MKNK1, MKNK2, MAP4K5 | EGFR 2624/4885ALDH1A1 2000/4885ADORA2A 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.